A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer

Trial Profile

A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2018

At a glance

  • Drugs Sorafenib (Primary) ; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms TIES
  • Most Recent Events

    • 10 May 2018 Status changed from active, no longer recruiting to completed.
    • 11 Apr 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019 ((this is the expected last completion date for patients who have remained in follow-up post-trial completion)).
    • 15 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2021 (this is the expected last completion date for patients who have remained in follow-up post-trial completion).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top